Drug Profile
Transdermal felodipine
Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Lavipharm S.A.; Pierre Fabre
- Class Antihypertensives; Dihydropyridines
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension in France (Transdermal, Patch)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension in Greece (Transdermal, Patch)